The First Affiliated Hospital of Soochow University

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

185

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

26 drugs in development

Phase 35

Phase 212

Phase 16

Preclinical6

By Therapeutic Area

top 5

Oncology

1757%

Immunology

13%

Respiratory

13%

Hematology

13%

Neurology

13%

R&D Momentum

81/100

Pipeline Velocity

52/100

Trial Completion Rate

88/100

Pipeline Concentration

42/100

Pipeline Freshness

60/100

Strategic Signals

↗Active in Immunology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 10, 2026

Recruiting

A Single-arm, Multi-center, Prospective Clinical Study of Mitoxantrone Hydrochloride Liposome Injection-based CMOP±R Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma

Sep 10, 2026

Active, not recruiting

Study of A Venetoclax-based, Anthracycline-free Regimen in Patients With Newly Diagnosed CBFβ::MYH11-positive Acute Myeloid Leukemia

Earlier

Sep 3, 2026TrialEfficacy and Safety of PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Sep 3, 2026TrialA Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety and Efficacy of U69 in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL)

Sep 3, 2026TrialStudy of the Efficacy and Safety of Venetoclax Plus Azacytidine Versus Daunorubicin Plus Cytarabine in Adult Acute Myeloid Leukemia (AML) Patients With Adverse Risk Features

Sep 3, 2026TrialSafety and Efficacy of CD22/CD19 CAR T-cells and Autologous HSCT Sandwich Strategy as Consolidation Therapy for B-cell Acute Lymphoblastic Leukemia

Aug 20, 2026TrialA Single-Arm, Prospective Clinical Study of the Efficacy and Safety of VABu Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Non-High-Risk AML Patients in CR1 With Low Performance Status (ECOG ≥ 2) or High Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI ≥ 2)

Aug 20, 2026TrialA Single-Center, Single-Arm, Open-Label, Phase II Clinical Trial of Sonrotoclax, Glofitamab, Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Large B-Cell Lymphoma

4 more events

Aug 13, 2026TrialSafety and Feasibility of Selective Fecal Microbiota Transplantation (FMT) for Immune Reconstitution in Immunodeficient Patients After Hematopoietic Stem Cell Transplantation (HSCT)

Aug 7, 2026TrialA Prospective, Randomized, Open-Label Study of Venetoclax Combined With Azacitidine for Consolidation Therapy in Adult Intermediate-Risk Acute Myeloid Leukemia

Aug 7, 2026TrialA Prospective, Randomized, Open-Label Study of Venetoclax Combined With Azacitidine for Consolidation Therapy in Adult Acute Myeloid Leukemia

Aug 7, 2026TrialExposure-Response and Prognostic Analysis of Venetoclax Therapeutic Drug Monitoring in Newly Diagnosed AML

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Hematology(1 drug)

—

Hematology(1 drug)

Immunology(1 drug)

—

Immunology(1 drug)

Neurology(1 drug)

—

Neurology(1 drug)

Oncology(17 drugs)

—

Oncology(17 drugs)

Respiratory(1 drug)

—

Respiratory(1 drug)

Unknown / Other(9 drugs)

—

Unknown / Other(9 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)